Second Beloranib Study Death Sinks Zafgen
This article was originally published in Scrip
Executive Summary
Shares of Zafgen Inc. plunged 63% on Dec. 2 after the company reported a second patient taking the firm's experimental Prader-Willi syndrome (PWS) drug beloranib had died of a bilateral pulmonary emboli.